<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/ZQ6R-KD69 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-17: Analysis of Nanoparticle Effects on Leukocyte Procoagulant Activity</p><p><b>Protocol Abbreviation:</b> ITA-17</p><p><b>Protocol Version:</b> 3<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/ZQ6R-KD69 >http://dx.doi.org/10.17917/ZQ6R-KD69 </a></p><p><b>Protocol File:</b> protocols/20240411_12-43-57-566_NCL_Method_ITA-17.pdf<p><b>File Title:</b> ITA-17</p><p><b>Description:</b></b> This document describes a protocol for assessing the ability of a nanoparticle formulation to induce leukocyte procoagulant activity. This protocol includes two cell models: normal leukocytes, represented by PBMC isolated from blood of healthy donor volunteers, and acute promyelocytic leukemia cells, represented by the HL-60 cell line. Briefly, cells are treated with nanoparticles, and then undergo a wash step to remove excess particles. Isolated cells are then used to initiate plasma coagulation, which is measured using coagulometer (following NCL protocol ITA-12) for analysis of prothrombin time.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>